Home › Research › Tau biomarkers
Lexical and Acoustic Speech Features Relating to Alzheimer Disease Pathology
Cho S, Cousins KAQ, Shellikeri S, Ash S, Irwin DJ, Liberman MY, Grossman M, Nevler N.. Neurology, 2022-07-25
Topic: Amyloid, tau and blood-test diagnosis
Background and objectives We compared digital speech and language features of patients with amnestic Alzheimer disease (aAD) or logopenic variant primary progressive aphasia (lvPPA) in a biologically confirmed cohort and related these features to neuropsychiatric test scores and CSF analytes. Methods We included patients with aAD or lvPPA with CSF (phosphorylated tau ([p-tau]/β-amyloid [Aβ] ≥0.09, and total tau/Aβ ≥0.34) or autopsy confirmation of AD pathology and age-matched healthy controls (HC) recruited at the Frontotemporal Degeneration Center of the University of Pennsylvania for a cross-sectional study. We extracted speech and language variables with automated lexical and acoustic pipelines from participants' oral picture descriptions.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Cho, S., Cousins, K. A. Q., Shellikeri, S., Ash, S., Irwin, D. J., Liberman, M. Y., et al. (2022). Lexical and Acoustic Speech Features Relating to Alzheimer Disease Pathology. Neurology. https://doi.org/10.1212/wnl.0000000000200581
Vancouver
Cho S, Cousins KAQ, Shellikeri S, Ash S, Irwin DJ, Liberman MY, et al. Lexical and Acoustic Speech Features Relating to Alzheimer Disease Pathology. Neurology. 2022. doi:10.1212/wnl.0000000000200581. PMID: 35487701.
BibTeX
@article{cho2022-35487701,
author = {Cho, S. and Cousins, K. A. Q. and Shellikeri, S. and Ash, S. and Irwin, D. J. and Liberman, M. Y. and Grossman, M. and Nevler, N.},
title = {{Lexical and Acoustic Speech Features Relating to Alzheimer Disease Pathology}},
journal = {Neurology},
year = {2022},
doi = {10.1212/wnl.0000000000200581},
pmid = {35487701},
url = {https://doi.org/10.1212/wnl.0000000000200581}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Methods We included patients with aAD or lvPPA with CSF (phosphorylated tau ([p-tau]/β-amyloid [Aβ] ≥0.09, and total tau/Aβ ≥0.34) or autopsy confirmation of AD pathology and age-matched healthy controls (HC) recruited at the Frontotemporal Degeneration Center of the University of Pennsylvania for a cross-sectional study.
- We extracted speech and language variables with automated lexical and acoustic pipelines from participants' oral picture descriptions.
- We compared the groups and correlated distinct features with clinical ratings and CSF p-tau levels.
- Results We examined patients with aAD (n = 44; age 62 ± 8 years; 24 women; Mini-Mental State Examination [MMSE] score 21.1 ± 4.8) or lvPPA (n = 21; age 64.1 ± 8.2 years; 11 women; MMSE score 23.0 ± 4.2) and HC (n = 28; age 65.9 ± 5.9 years, 15 women; MMSE score 29 ± 1).
Why it matters
This cross-sectional study compared automated speech and language features in patients with biologically confirmed Alzheimer disease and healthy controls, and related them to test scores and CSF analytes. It is a single-time-point study, so it cannot show whether speech changes predict or respond to treatment.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designcross-sectional
- Participants44
- Evidence strengthModerate
How this study scored 55/100
Published in a leading specialty journal, and it is a snapshot of people at one point in time. Scored zero for effect reported and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Neurology) |
| Journal's citation record | 4 / 4 | Neurology: journal h-index 525 (OpenAlex, 2026-10-29) |
| Study design | 4 / 12 | A snapshot of people at one point in time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2022 — within 6 year(s) of the newest study here |
| Sample size | 1 / 4 | 44 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 50 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 8.3 citations a year over 6 year(s) since 2022 |
| Impact for its field and year | 3 / 6 | Cited 5.4× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 2 / 4 | Cited 38 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Naomi Nevler: h-index 15 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of Pennsylvania: institution h-index 1,859 (OpenAlex) |
| Multi-centre collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 35487701) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 55 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Tau biomarkers
Also in Tau biomarkers
66 studies in the library are filed under Tau biomarkers with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Tau biomarkers hub.